News
Approximately 9,000 CVS locations will begin selling Wegovy for $499 per month to customers who pay cash out of pocket.
CVS’s stock surges toward a one-year high after profit and revenue beat expectations, amid strength in the pharmacy business, ...
Starting on July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial ...
Aetna is once again retreating from the Affordable Care Act market, while its parent company notched a deal with Danish ...
Wegovy to become preferred GLP-1 drug on CVS Caremark's top formularies in 2025 as Novo Nordisk expands patient access ...
The deal could expand access to its in-demand obesity drug at the expense of Eli Lilly, whose shares fell by double digits on ...
Novo Nordisk A/S said it would sell its popular weight-loss drug Wegovy for a steeply reduced price on several telehealth ...
Effective July 1, 2025, CVS Caremark will place Wegovy injection 2.4 mg as preferred on its commercial template formularies.
Eli Lilly’s strong quarterly results were overshadowed by CVS’s decision to favour Novo Nordisk’s Wegovy over Zepbound.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback